Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.


Great Partnership´s Mission

European and African researchers from eight different organizations have teamed up to advance a HIV vaccine candidate, HIVconsvX, designed to prevent infection throughout the world. The novel vaccine construct is designed to address the variability of HIV-1, which presents one of the greatest challenges to introducing an effective vaccine. Such a vaccine is critical to ending the HIV/AIDS epidemic.

Professor Tomáš Hanke of the Jenner Institute at the University of Oxford is leading the programme to evaluate the vaccine candidate in Europe and Africa, in collaboration with Imperial College LondonIAVIKAVI-Institute for Clinical ResearchKEMRI-Wellcome Trust Research Programme, the Medical Research Council at the Uganda Virus Research Institute on AIDS, the UVRI-IAVI HIV Vaccine Program in Uganda and the Center for Family Health Research in Zambia. The programme is supported by the European & Developing Countries Clinical Trials Partnership (EDCTP)